Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1294654 | 0.85 | L3MBTL1 (0.41) | MAPTKDM4EMAPK1RARBRARG | |
| SCHEMBL12333342 | 0.81 | ESR2 (0.49) | ESR2NR1H2CRBNDDB1MAPT | |
| SCHEMBL1294136 | 0.81 | ESR2 (0.50) | ESR2NR1H2CRBNDDB1MAPT | |
| SCHEMBL12106764 | 0.78 | ESR2 (0.48) | ESR2NR1H2CRBNDDB1MAPT | |
| SCHEMBL1294170 | 0.77 | ESR2 (0.46) | ESR2NR1H2CRBNDDB1MAPT | |
| SCHEMBL12110212 | 0.76 | RARB (0.38) | RARBRARG | |
| SCHEMBL12106768 | 0.74 | ESR2 (0.44) | ESR2NR1H2CRBNDDB1MAPT | |
| SCHEMBL12333344 | 0.74 | ESR2 (0.48) | ESR2NR1H2CRBNDDB1MAPT | |
| SCHEMBL12333107 | 0.74 | POLB (0.47) | ESR2NR1H2CRBNDDB1MAPT | |
| SCHEMBL12106989 | 0.73 | ESR2 (0.53) | ESR2NR1H2CRBNDDB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598434-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-9108977-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130012496-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130012496-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-10 | — | — | US | disclosed |
| WO-2011111817-A1 | BENZAZEPINE COMPOUND | アステラス製薬株式会社 (JP) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012496-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | ESR2 182/4885NR1H2 1241/4885CRBN 3951/4885 |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | ESR2 182/4885NR1H2 1241/4885CRBN 3951/4885 |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | ESR2 182/4885NR1H2 1241/4885CRBN 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.